NCT05816759View on ClinicalTrials.gov

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

June 4, 2023

Study Completion Date

June 22, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

CKD-383

QD, PO

DRUG

CKD-501, D744, D150

QD, PO

Trial Locations (1)

13497

CHA Bundang Medical Center, CHA University, Seongnam-si

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY